<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542190</url>
  </required_header>
  <id_info>
    <org_study_id>0018014600011</org_study_id>
    <nct_id>NCT01542190</nct_id>
  </id_info>
  <brief_title>Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery</brief_title>
  <official_title>A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare effects of preoperative and postoperative use of
      topical ketorolac tromethamine 0.4% versus placebo in uncomplicated cataract surgery.

      Patients scheduled to undergo phacoemulsification will be randomized to receive either
      topical prednisolone acetate 1% 4 times daily (QID) plus dextran 70/hypromellose QID (placebo
      group) or topical prednisolone 1% QID plus ketorolac tromethamine 0.4% QID (ketorolac group)
      for three days preoperatively and four weeks postoperatively. The primary outcome 5 weeks
      after surgery will be angiographic cystoid macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      To compare effects of preoperative and postoperative use of topical ketorolac tromethamine
      0.4% versus placebo in uncomplicated cataract surgery.

      Methods:

      This will be a masked single-center, randomized clinical study comprising 80 patients
      undergoing phacoemulsification cataract surgery. Patients scheduled to undergo
      phacoemulsification and with no recognized cystoid macular edema (CME) risks (diabetic
      retinopathy, retinal vascular disease or macular abnormality) will be randomized to receive
      either topical prednisolone acetate 1% 4 times daily (QID) plus dextran 70/hypromellose QID
      (placebo group;n=40) or topical prednisolone 1% QID plus ketorolac tromethamine 0.4% QID
      (ketorolac group;n=40) for three days preoperatively and four weeks postoperatively. In both
      groups topical gatifloxacin will be administered to the treated eye QID, starting three days
      before surgery and continuing for seven days. The primary outcome 5 weeks after surgery will
      be angiographic cystoid macular edema. Other included outcomes will be best corrected visual
      acuity (BCVA), intraocular pressure (IOP), CME incidence, retinal thickness as measured by
      spectral-domain optical coherence tomography (OCT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cystoid macular edema</measure>
    <time_frame>1 month</time_frame>
    <description>Angiography (Miyake's criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 month</time_frame>
    <description>ETDRS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cystoid Macular Edema Following Cataract Surgery, Bilateral</condition>
  <arm_group>
    <arm_group_label>ketorolac tromethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrano 70 / Hypromellose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <description>ketorolac tromethamine 0.4%</description>
    <arm_group_label>ketorolac tromethamine</arm_group_label>
    <arm_group_label>Dextrano 70 / Hypromellose</arm_group_label>
    <other_name>Acular LS (Allergan)</other_name>
    <other_name>Lacribell (Latinofarma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with nuclear cataract, density 1 and 2 classified by LOCS II, scheduled to
             undergo phacoemulsification cataract surgery.

        Exclusion Criteria:

          -  Patients with:

               -  Diabetes,

               -  Hypertension,

               -  uveitis,

               -  macular disease,

               -  congenital ocular abnormalities,

               -  cataract density 0 and 3 by LOCS II,

               -  pseudoexfoliation syndrome.

        Patients under treatment with nonsteroidal antinflammatory drugs or topical eye drops were
        excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo PC Lira</last_name>
    <role>Study Chair</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13083970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.fcm.unicamp.br</url>
    <description>Estate University of Campinas</description>
  </link>
  <reference>
    <citation>Miyake K, Masuda K, Shirato S, Oshika T, Eguchi K, Hoshi H, Majima Y, Kimura W, Hayashi F. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol. 2000 Jan-Feb;44(1):58-67.</citation>
    <PMID>10698027</PMID>
  </reference>
  <reference>
    <citation>Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S203-18. Review.</citation>
    <PMID>12204717</PMID>
  </reference>
  <reference>
    <citation>Kim A, Stark WJ. Are topical NSAIDs needed for routine cataract surgery? Am J Ophthalmol. 2008 Oct;146(4):483-5. doi: 10.1016/j.ajo.2008.07.027.</citation>
    <PMID>18804560</PMID>
  </reference>
  <reference>
    <citation>Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch Ophthalmol. 1966 Nov;76(5):646-61.</citation>
    <PMID>5955948</PMID>
  </reference>
  <reference>
    <citation>Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1977 Aug 8;203(2):81-8.</citation>
    <PMID>303062</PMID>
  </reference>
  <reference>
    <citation>Miyake K, Ota I, Miyake G, Numaga J. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. J Cataract Refract Surg. 2011 Sep;37(9):1581-8. doi: 10.1016/j.jcrs.2011.03.052.</citation>
    <PMID>21855758</PMID>
  </reference>
  <reference>
    <citation>Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology. 1998 Mar;105(3):397-405.</citation>
    <PMID>9499767</PMID>
  </reference>
  <reference>
    <citation>Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008 Oct;146(4):554-560. doi: 10.1016/j.ajo.2008.04.036. Epub 2008 Jul 2.</citation>
    <PMID>18599019</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Joao Paulo Felix</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>cataract surgery</keyword>
  <keyword>cystoid macular edema</keyword>
  <keyword>angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

